2019
Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
Yu J, Iorio A, Edginton A, co‐investigators O, Ahuja S, Román M, Arrieta M, Arola M, Barillari G, Balasa V, Belletrutti M, Moreno R, Beurrier P, Bidlingmaier C, Blanchette V, Blatny J, Bonanad S, Brose K, Brown D, Byant P, Canaro M, Carvalho M, Catarino C, Chitlur M, Cockrell E, Chowdary P, Cnossen M, Collins P, Coppens M, Croteau S, Cultrera D, de Cristofaro R, de Raucourt E, Desprez D, Dunn A, El‐Ekiabi M, Kotnik B, Fischer K, Frotscher B, Garbiero S, Ruiz R, Gill J, del Castillo C, Gottstein S, Lassandro G, Giordano P, Hart D, Hegemann I, Hermans C, Hua B, Hwang N, Jackson S, James P, Katsarou O, Kavakli K, Kempton C, Kentouche K, Khan O, Kobelt R, Kruse‐Jarres R, Laane E, Larson E, Lassila R, Lee A, Poon M, Lissick J, Langstrom S, Mahlangu J, Makris M, Marchesini E, Mateo J, Vera P, Martorell M, Matsushita T, McCrae S, Mignot‐Castellano E, Montcrieff C, Maes P, Mondelars V, Bekart M, Mora E, Morales J, Mourey G, Bertrand M, Napolitano M, Siragusa S, Negrier C, Neme D, Niinimaki R, Oldenburg J, Albert T, Ornstein D, Ozelo M, Panetta J, Neufeld E, P'Ng S, Peerlinck K, Pollio B, Pouplard C, Gruel Y, Prezotti A, Price V, Primacakti F, Puyade M, Radossi P, Raffini L, Ragni M, Rangarajan S, Reding M, Reid R, Restrepo J, Ramirez J, Recht M, Lopez M, Ruiz‐Sàez A, Saleh M, Shapiro A, Sharathkumar A, Selmeczi A, Simpson M, Singleton T, Cruz M, Soto V, Steele M, Streif W, Sun H, Ritchie B, Sun J, Feng X, Suzuki T, Nagao A, Takemoto C, Tapp H, Teitel J, Tinmouth A, Thornburg C, Tosseto A, Turnstall O, Vezina C, Warren B, Wheeler A, Gutierrez J, Wu J, Wynn T, Yang R, Young G, Zanon E, Zupan I. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research And Practice In Thrombosis And Haemostasis 2019, 3: e12204. PMID: 31294337, PMCID: PMC6611373, DOI: 10.1002/rth2.12204.Peer-Reviewed Original ResearchClotting factor productsFactor concentrationsClotting factorsPrediction of pharmacokineticsDosing regimenClinical benefitHemophilia patientsInadequate dosingTitrated treatmentComparative pharmacokinetic studyPharmacokinetic studiesSecondary objectivesRisks associated with switchingDevelopment studiesHemophiliaPharmacokineticsPatientsFactor productivityInhibitor developmentProphylaxisClotPK knowledgeDoseInhibitorsRegimen
2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle albumin-bound paclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-bound paclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply